Manufacturing of life-enhancing medicines boosted by new government funding

22 Nov 2018

Patients could receive faster treatment following boost to streamline the production of medicines and treatments.

Patients could soon receive faster treatment thanks to a multimillion pound government boost to streamline the production of medicines and treatments, including those used to treat blood cancers and inherited disorders.

Manufacturing of life-enhancing medicines boosted by new government funding

Companies in Northumberland, Oxford and London will adopt new digital technologies, such as artificial intelligence, to support the manufacture of next-generation medicines and treatments.

The £4.3 million funding aims to create more efficient and innovative methods for manufacturing medicines. The challenge works to set the UK apart as a leader with greater capacity for manufacture of safe, affordable and effective therapies.

Life Sciences Minister Lord Henley said: "New technology can help us live longer, healthier lives and the new projects announced today will improve the speed and accuracy with which medicines get to the people that need them.

"Advances in technology can help us address the challenges that an ageing society presents and we are backing the technologies of tomorrow in our modern Industrial Strategy, with the biggest increase in public research and development investment in UK history."

The three individual projects are:

  • Arc Trinova in Northumberland will use new technologies to speed up the process of the production of patient-specific medicines; it is currently a timely process dispensing individual doses from bulk because of the careful handling, labelling and batch release processes.
  • Oxford Biomedica will look to dramatically reduce the supply time for manufacturing by using a new digital and robotics framework to increase capacity, reduce waste and cut costs.
  • Autolus in London will look to avoid mix-ups of complex medicines on the supply chain by developing a computer-based system that will constantly monitor the operation, making adjustments to timing, co-ordination and production where necessary, improving the efficiency of the whole system and working at a pace that human operators cannot imitate.
  • One year on from the launch of the Industrial Strategy, this £7.3 million investment is the latest commitment from the £180 million Industrial Strategy Challenge Fund (ISCF) dedicated to leading-edge Medicines Manufacturing.

    Taking steps to improve patient access to life-saving treatments and medicines, Advanced Therapy Treatment Centres, working across the UK, will support the roll-out of cell and gene therapies as clinical trials show them to be safe and cost-effective. The centres bring together expert clinicians, researchers, scientists, developers and private companies to demonstrate how the therapies have impact on patients’ lives.

    Advanced therapies, including cell and gene therapies, represent the next generation of therapies that have the potential to offer treatments for a number of conditions including some blood cancers and inherited conditions for which there are currently limited treatment options.

    UK Research and Innovation (UKRI) is responsible for managing the Industrial Strategy Challenge Fund, which funds the winners of the Medicines Manufacturing Challenge.

    Dr Ian Campbell, Interim Executive Chair, Innovate UK for UKRI, said: "The projects announced today will bring real benefits to patients and boost the knowledge economy as part of the government’s modern Industrial Strategy. This is vital for the UK as a global leader in the development of advanced therapies and medicine manufacturing."

    Read More

    Related news

    Can the industry really claim it's 'business as usual'?

    Can the industry really claim it's 'business as usual'?

    19 May 2020

    ChargePoint Technology's Chief Commercial Officer says "yes" it can.

    Read more 
    HKBU scientists develop technique to eliminate drug side effects

    HKBU scientists develop technique to eliminate drug side effects

    19 May 2020

    The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

    Read more 
    Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

    Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

    19 May 2020

    The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

    Read more 
    Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

    Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

    18 May 2020

    CDMO is contracted to produce multiple clinical batches from German facility

    Read more 
    Pharmapack expert recommends holistic approach to sustainability

    Pharmapack expert recommends holistic approach to sustainability

    18 May 2020

    Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

    Read more 
    KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

    KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

    12 May 2020

    Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

    Read more 
    Characterizing virus and virus-like particles

    Characterizing virus and virus-like particles

    12 May 2020

    New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

    Read more 
    Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

    Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

    12 May 2020

    CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

    Read more 
    AI technology company launches with Novartis and Sarepta deals

    AI technology company launches with Novartis and Sarepta deals

    11 May 2020

    Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

    Read more 
    Demand for immunity products to be sustained long-term says SIRIO

    Demand for immunity products to be sustained long-term says SIRIO

    11 May 2020

    Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

    Read more